EnglishSIndan, a developer, producer and distributor of oncologic products, has become Actavis Romania following the acquisition in March 2006 of Sindan Pharma by Actavis - Iceland for 147.5 million EUR. Actavis" financial report indicates that sales on the Romanian market amounted to 5% of the group-wide sales figure of 1.31 billion EUR.
Sindan continued to develop after the acquisition and posted Y2006 revenues of 95 million EUR, of which 10 million EUR from exports. Estimates for this year indicate revenues of 115 million EUR, of which 15 million EUR from exports.
Actavis Romania could become an oncologic drug export platform to Europe, the US and Asia, as projections indicate exports of 100 million EUR in 2009 and a new drug factory in 2010. As Actavis Romania is the only oncologic drug production unit of Actavis, the group intends to invest 50 million EUR in the new factory.
Sindan was established in Bucharest in 1991 and currently has some 280 employees across the country. The company has distribution networks in Japan, Britain, Poland, Hungary, Slovakia, Bulgaria and Moldova. Actavis is based in Iceland and operates in 32 countries with 11,000 employees. Last year"s turnover was 1.4 billion EUR.
Euro
Dolar SUA
Franc elveţian
Liră sterlină
Gram de aur
